Literature DB >> 21136903

Urinary proteomic analysis of chronic allograft nephropathy.

Edmond O'Riordan1, Tatyana N Orlova, Natalia Mendelev, Daniel Patschan, Rowena Kemp, Praveen N Chander, Rena Hu, Gang Hao, Steven S Gross, Renato V Iozzo, Veronica Delaney, Michael S Goligorsky.   

Abstract

The pathogenesis of progressive renal allograft injury, which is termed chronic allograft nephropathy (CAN), remains obscure and is currently defined by histology. Prospective protocol-biopsy trials have demonstrated that clinical and standard laboratory tests are insufficiently sensitive indicators of the development and progression of CAN. The study aim was to determine if CAN could be characterized by urinary proteomic data and identify the proteins associated with disease. The urinary proteome of 75 renal transplant recipients and 20 healthy volunteers was analyzed using surface enhanced laser desorption and ionization MS. Patients could be classified into subgroups with normal histology and Banff CAN grades 2-3 with a sensitivity of 86% and a specificity of 92% by applying the classification algorithm Adaboost to urinary proteomic data. Several urinary proteins associated with advanced CAN were identified including α1-microglobulin, β2-microglobulin, prealbumin, and endorepellin, the antiangiogenic C-terminal fragment of perlecan. Increased urinary endorepellin was confirmed by ELISA and increased tissue expression of the endorepellin/perlecan ratio by immunofluoresence analysis of renal biopsies. In conclusion, analysis of urinary proteomic data has further characterized the more severe CAN grades and identified urinary endorepellin, as a potential biomarker of advanced CAN.
Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Year:  2008        PMID: 21136903      PMCID: PMC4690473          DOI: 10.1002/prca.200780137

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  44 in total

1.  Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. I. Profiling an unfractionated tryptic digest.

Authors:  C S Spahr; M T Davis; M D McGinley; J H Robinson; E J Bures; J Beierle; J Mort; P L Courchesne; K Chen; R C Wahl; W Yu; R Luethy; S D Patterson
Journal:  Proteomics       Date:  2001-01       Impact factor: 3.984

2.  Protocol biopsies and risk factors associated with chronic allograft nephropathy.

Authors:  D Serón; F Moreso
Journal:  Transplant Proc       Date:  2002-02       Impact factor: 1.066

3.  Development of a high-throughput method for preparing human urine for two-dimensional electrophoresis.

Authors:  Graeme Smith; Derek Barratt; Rachel Rowlinson; Janice Nickson; Robert Tonge
Journal:  Proteomics       Date:  2005-06       Impact factor: 3.984

Review 4.  Lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan) and atherogenicity.

Authors:  S Pillarisetti
Journal:  Trends Cardiovasc Med       Date:  2000-02       Impact factor: 6.677

5.  BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan.

Authors:  Eva M Gonzalez; Charles C Reed; Gregory Bix; Jian Fu; Yue Zhang; Bagavathi Gopalakrishnan; Daniel S Greenspan; Renato V Iozzo
Journal:  J Biol Chem       Date:  2004-12-09       Impact factor: 5.157

6.  Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies.

Authors:  Daniel Serón; Francesc Moreso; Xavier Fulladosa; Miguel Hueso; Marta Carrera; Josep M Grinyó
Journal:  Kidney Int       Date:  2002-02       Impact factor: 10.612

7.  Toward proteomics in uroscopy: urinary protein profiles after radiocontrast medium administration.

Authors:  Dierk J Hampel; Christine Sansome; M A Sha; Sergey Brodsky; William E Lawson; Michael S Goligorsky
Journal:  J Am Soc Nephrol       Date:  2001-05       Impact factor: 10.121

8.  Bioinformatic analysis of the urine proteome of acute allograft rejection.

Authors:  Edmond O'Riordan; Tatyana N Orlova; Jianfeng Mei J; Khalid Butt; Praveen M Chander; Shafiq Rahman; Muong Mya; Rena Hu; Jahangir Momin; Elizabeth W Eng; Dierk J Hampel; Bertram Hartman; Matthias Kretzler; Veronica Delaney; Michael S Goligorsky
Journal:  J Am Soc Nephrol       Date:  2004-12       Impact factor: 10.121

9.  The natural history of chronic allograft nephropathy.

Authors:  Brian J Nankivell; Richard J Borrows; Caroline L-S Fung; Philip J O'Connell; Richard D M Allen; Jeremy R Chapman
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

10.  The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation.

Authors:  E Dimény; G Tufveson; H Lithell; E Larsson; A Siegbahn; B Fellström
Journal:  Eur J Clin Invest       Date:  1993-09       Impact factor: 4.686

View more
  19 in total

Review 1.  Microvascular rarefaction: the decline and fall of blood vessels.

Authors:  Michael S Goligorsky
Journal:  Organogenesis       Date:  2010 Jan-Mar       Impact factor: 2.500

Review 2.  The nature and biology of basement membranes.

Authors:  Ambra Pozzi; Peter D Yurchenco; Renato V Iozzo
Journal:  Matrix Biol       Date:  2016-12-28       Impact factor: 11.583

Review 3.  Application of proteomic analysis to the study of renal diseases.

Authors:  Matthew P Welberry Smith; Rosamonde E Banks; Steven L Wood; Andrew J P Lewington; Peter J Selby
Journal:  Nat Rev Nephrol       Date:  2009-10-27       Impact factor: 28.314

Review 4.  Danger signals in regulating the immune response to solid organ transplantation.

Authors:  Jamie L Todd; Scott M Palmer
Journal:  J Clin Invest       Date:  2017-05-22       Impact factor: 14.808

Review 5.  The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy.

Authors:  Stephen Douglass; Atul Goyal; Renato V Iozzo
Journal:  Connect Tissue Res       Date:  2015-07-16       Impact factor: 3.417

Review 6.  Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers.

Authors:  Chiara Poluzzi; Renato V Iozzo; Liliana Schaefer
Journal:  Adv Drug Deliv Rev       Date:  2015-10-27       Impact factor: 15.470

Review 7.  Proteomics for rejection diagnosis in renal transplant patients: Where are we now?

Authors:  Wilfried Gwinner; Jochen Metzger; Holger Husi; David Marx
Journal:  World J Transplant       Date:  2016-03-24

8.  Excretion of anti-angiogenic proteins in patients with chronic allograft dysfunction.

Authors:  Eliza Moskowitz-Kassai; Lina Mackelaite; Jun Chen; Kaushal Patel; Darshana M Dadhania; Steven S Gross; Praveen Chander; Vera Delaney; Luqin Deng; Ligong Chen; Xiangqin Cui; Manikkam Suthanthiran; Michael S Goligorsky
Journal:  Nephrol Dial Transplant       Date:  2012-01-17       Impact factor: 5.992

Review 9.  Diverse cell signaling events modulated by perlecan.

Authors:  John M Whitelock; James Melrose; Renato V Iozzo
Journal:  Biochemistry       Date:  2008-10-01       Impact factor: 3.162

Review 10.  A current view of perlecan in physiology and pathology: A mosaic of functions.

Authors:  Maria A Gubbiotti; Thomas Neill; Renato V Iozzo
Journal:  Matrix Biol       Date:  2016-09-06       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.